select trial semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the Novo's obesity drug cuts risk

doi:10.1042/0264-6021:3600001

Plasma concentrations measure approximately 200 ng/mL at age 20 and decline to approximately 80 ng/mL by age 60

Tirzepatide demonstrated a 94% reduction in progression from prediabetes to diabetes in the SURMOUNT trials, the most effective diabetes prevention ever documented in clinical research

The 'Wild West' Marketplace: Contamination and Counterfeits Because these peptides are not FDA-approved, they are manufactured in unregulated labs and sold as 'research chemicals not for human consumption' a transparent legal loophole

Yes for hormone replacement therapy and GLP-1 medicationswe need baseline labs to dose correctly and monitor response